Key Points
- EVP Paul Mahon sold 8,300 shares of United Therapeutics on Feb. 19 at an average price of $476.34 for proceeds of $3,953,622, reducing his holding by 18.41% to 36,781 shares (about $17.52M).
- UTHR shares traded around $471.17 mid-day (52-week range $266.98–$519.99) with a market cap of ~$20.3B, and analysts have an average rating of "Moderate Buy" with a mean price target of $509.50.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the firm's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $476.34, for a total value of $3,953,622.00. Following the sale, the executive vice president directly owned 36,781 shares in the company, valued at approximately $17,520,261.54. The trade was a 18.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
United Therapeutics Price Performance
Shares of UTHR stock traded down $9.35 during mid-day trading on Friday, hitting $471.17. 28,212 shares of the stock traded hands, compared to its average volume of 320,933. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99. The stock has a market cap of $20.29 billion, a P/E ratio of 17.81, a P/E/G ratio of 2.53 and a beta of 0.85. The stock's fifty day moving average is $485.69 and its two-hundred day moving average is $437.84.
Hedge Funds Weigh In On United Therapeutics
A number of institutional investors have recently bought and sold shares of UTHR. Torren Management LLC purchased a new stake in shares of United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management boosted its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC grew its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $31,000. 94.08% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on UTHR. Wells Fargo & Company upped their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 30th. Royal Bank Of Canada upped their target price on United Therapeutics from $569.00 to $587.00 and gave the company an "outperform" rating in a research report on Thursday, October 30th. UBS Group reissued a "buy" rating on shares of United Therapeutics in a report on Tuesday. HC Wainwright upped their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the company a "buy" rating in a report on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research report on Wednesday, October 29th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $509.50.
Check Out Our Latest Research Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
